Trial Profile
Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs AUTO 2 (Primary) ; Interferon alpha (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms ACTME
- 11 Dec 2023 Planned End Date changed from 1 Nov 2023 to 29 Nov 2025.
- 11 Dec 2023 Planned primary completion date changed from 1 Nov 2022 to 29 Nov 2025.
- 11 Dec 2023 Status changed from recruiting to active, no longer recruiting.